PILRA Gene

PILRA (Paired Immunoglobulin-Like Type 2 Receptor Alpha)

Overview

PILRA (Paired Immunoglobulin-Like Type 2 Receptor Alpha), also known as PILRα, is an inhibitory immune receptor expressed primarily on cells of the immune system. The gene is located on chromosome 7q22.1 and encodes a type I transmembrane protein belonging to the paired immunoglobulin-like receptor family. PILRα plays critical roles in immune regulation by modulating the activation of various immune cell types, including T cells, natural killer (NK) cells, dendritic cells, and macrophages. This receptor has been extensively studied for its role in immune cell signaling and has recently gained attention for its involvement in neurodegenerative diseases.

In the central nervous system, PILRα is expressed on microglia, the resident immune cells of the brain, where it regulates neuroinflammatory responses. Recent genetic studies have identified PILRA variants associated with increased risk for Alzheimer's disease and Parkinson's disease, highlighting its importance in neurodegeneration [@kim2020]. The receptor interacts with CD99 and other ligands to modulate immune responses, making it a potential therapeutic target for neuroinflammatory conditions.

<div class="infobox infobox-gene">

PILRA (Paired Immunoglobulin-Like Type 2 Receptor Alpha)

Overview

PILRA (Paired Immunoglobulin-Like Type 2 Receptor Alpha), also known as PILRα, is an inhibitory immune receptor expressed primarily on cells of the immune system. The gene is located on chromosome 7q22.1 and encodes a type I transmembrane protein belonging to the paired immunoglobulin-like receptor family. PILRα plays critical roles in immune regulation by modulating the activation of various immune cell types, including T cells, natural killer (NK) cells, dendritic cells, and macrophages. This receptor has been extensively studied for its role in immune cell signaling and has recently gained attention for its involvement in neurodegenerative diseases.

In the central nervous system, PILRα is expressed on microglia, the resident immune cells of the brain, where it regulates neuroinflammatory responses. Recent genetic studies have identified PILRA variants associated with increased risk for Alzheimer's disease and Parkinson's disease, highlighting its importance in neurodegeneration [@kim2020]. The receptor interacts with CD99 and other ligands to modulate immune responses, making it a potential therapeutic target for neuroinflammatory conditions.

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | PILRA |
| Full Name | Paired Immunoglobulin-Like Type 2 Receptor Alpha |
| Chromosomal Location | 7q22.1 |
| NCBI Gene ID | 9317 |
| OMIM ID | 604866 |
| Ensembl ID | ENSG00000137216 |
| UniProt ID | Q9YH5Q |
| Encoded Protein | Paired immunoglobulin-like receptor alpha |
| Gene Type | Protein-coding |
| Protein Family | Paired immunoglobulin-like receptor family |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, multiple sclerosis, inflammatory disorders |

</div>

Structure and Function

Protein Structure

PILRα is a type I transmembrane glycoprotein with characteristic features:

The extracellular region consists of two immunoglobulin-like domains that mediate binding to various ligands, including CD99 and glycosylated ligands. The cytoplasmic tail contains ITIM sequences that, upon receptor engagement, recruit phosphatases (SHP-1, SHP-2) to transmit inhibitory signals.

Protein Topology and Domains

The detailed domain structure of PILRα includes:

| Domain | Position | Function |
|--------|----------|----------|
| Signal peptide | 1-19 | Targeting to plasma membrane |
| Ig-like V-type domain 1 | 20-110 | First ligand-binding domain |
| Ig-like C2-type domain | 111-190 | Second ligand-binding domain |
| Transmembrane region | 191-213 | Membrane anchoring |
| ITIM motif 1 | 241-246 | Inhibitory signaling (YXXL/V) |
| ITIM motif 2 | 262-267 | Secondary inhibitory motif |

Molecular Function

PILRα functions as an inhibitory immune receptor:

Signaling Pathways

ITIM-Mediated Inhibition:

SHP-1/SHP-2 Signaling Cascade:

Cross-talk with Activating Receptors:
PILRalpha often operates in concert with activating receptors to fine-tune immune responses. The balance between inhibitory and activating signals determines cellular responses. This is particularly important in microglia where PILRalpha modulates the response to amyloid-beta and alpha-synuclein.

Modulation of TREM2 Signaling:
Recent research suggests PILRalpha may interact with TREM2, another important microglial receptor involved in neurodegeneration. The interplay between these receptors may determine microglial phenotypic responses in AD and PD.

Role in Neurodegeneration

Alzheimer's Disease

PILRA has emerged as an important genetic risk factor for Alzheimer's disease:

Genetic Association:

• PILRA variants have been associated with AD risk in genome-wide studies [@hansen2019]
• Certain PILRA alleles increase susceptibility to AD
• The functional variants affect receptor expression and function
• GWAS hits in PILRA region have been replicated in multiple cohorts
• The rs2075650 locus shows consistent association with AD risk

Microglial Regulation:
PILRα is critical for microglial function in AD [@chen2020]:

• Regulates microglial activation states
• Modulates cytokine production
• Affects phagocytic activity
• Influences amyloid plaque interaction
• Controls complement system interaction

• PILRα affects microglial responses to amyloid-β
• Modulates Aβ clearance mechanisms
• Influences plaque-associated inflammation
• Affects Aβ aggregation kinetics

• PILRα regulates chronic neuroinflammation in AD
• Controls pro-inflammatory cytokine production
• Affects microglial survival and function
• Modulates NLRP3 inflammasome activity

• PILRα may influence tau phosphorylation
• Microglial-mediated neuronal damage affects tau spread
• Interaction with complement system affects tau clearance

Parkinson's Disease

In Parkinson's disease, PILRα plays important roles:

Dopaminergic Neuron Protection:

• PILRα is expressed on microglia surrounding dopaminergic neurons
• Regulates neuroinflammatory responses
• May influence dopaminergic neuron survival
• Modulates microglial surveillance of substantia nigra

• Modulates microglial responses to α-synuclein
• Affects aggregation and clearance
• Influences neuroinflammation in PD
• May affect Lewy body formation

• PILRα regulates chronic neuroinflammation
• Controls microglial activation
• Affects cytokine production
• Modulates T cell infiltration

Multiple Sclerosis

PILRα has been implicated in multiple sclerosis:

• Modulates T cell responses
• Affects immune cell trafficking
• Regulates demyelination processes
• May influence lesion formation

Amyotrophic Lateral Sclerosis

• PILRα in microglial responses
• May affect motor neuron survival
• Modulates neuroinflammation in ALS
• Potential biomarker value

Additional Neurodegenerative Conditions

Huntington's Disease:

• PILRα expression altered in HD
• May modulate mutant huntingtin responses
• Microglial activation affected

• Role in tauopathy contexts
• Microglial involvement
• Inflammatory modulation

• PILRα in prion-induced neurodegeneration
• Immune response modulation

Molecular Mechanisms

Immune Cell Functions

T Cells:

• PILRα inhibits T cell activation through ITIM signaling
• Modulates TCR signaling by recruiting SHP phosphatases
• Regulates cytokine production in activated T cells
• Influences T cell differentiation into various subsets
• Controls regulatory T cell function

• Controls NK cell cytotoxicity through inhibitory signaling
• Modulates cytokine secretion (IFN-γ, TNF-α)
• Affects NK cell maturation and activation state
• Regulates interaction with target cells

• Regulates antigen presentation to T cells
• Modulates T cell priming and polarization
• Controls cytokine production affecting adaptive immunity
• Affects dendritic cell migration and maturation

• Controls inflammatory responses to various stimuli
• Affects phagocytosis of pathogens and debris
• Regulates cytokine production (TNF-α, IL-6, IL-12)
• Modulates oxidative burst and antimicrobial activity

Signaling Network Integration

PILRα integrates with multiple signaling networks:

Key Signaling Cross-talk Points:

Microglial Mechanisms

Activation States:
PILRα regulates microglial polarization:

• Pro-inflammatory (M1) vs. anti-inflammatory (M2) states
• Cytokine production patterns
• Phagocytic capacity
• Antigen presentation capability

Neuroinflammation:

• Controls chronic neuroinflammation
• Affects cytokine and chemokine production
• Modulates cell-cell interactions
• Regulates inflammasome activation
• Controls reactive oxygen species production

• Affects complement-mediated clearance
• Modulates Fc receptor function
• Influences apoptotic cell clearance
• Regulates amyloid phagocytosis

Cytokine and Chemokine Regulation

PILRα modulates production of various inflammatory mediators:

| Mediator | Effect | Pathway |
|----------|--------|---------|
| TNF-α | Downregulated | NF-κB inhibition |
| IL-1β | Downregulated | NLRP3 modulation |
| IL-6 | Variable | Context-dependent |
| IL-10 | Upregulated | Anti-inflammatory |
| CCL2 | Downregulated | Reduced monocyte recruitment |
| CXCL10 | Modulated | IFN-γ pathway |

Expression Patterns

Immune Cell Expression

PILRA exhibits specific expression patterns across immune cell types:

| Cell Type | Expression Level | Functional Implication |
|-----------|-----------------|------------------------|
| T cells | High | Immune regulation, T cell inhibition |
| NK cells | High | Cytotoxicity control, cytokine modulation |
| Dendritic cells | Moderate | Antigen presentation, T cell priming |
| Macrophages | Moderate | Inflammation control, phagocytosis |
| B cells | Low | B cell function regulation |
| Monocytes | Moderate | Innate immune response |
| Neutrophils | Low | Inflammatory responses |

Brain Expression

In the central nervous system, PILRα shows distinct expression patterns:

• Microglia: Primary immune cell expressing PILRα in brain, high levels in resting and activated states
• Neurons: Low to moderate expression, higher in certain neuronal populations
• Astrocytes: Limited expression, variable across brain regions
• Oligodendrocytes: Low expression, potential role in myelin maintenance
• Endothelial cells: Moderate expression, blood-brain barrier interaction

Tissue Distribution

PILRA is expressed in various peripheral tissues:

• Spleen: High expression, immune cell populations
• Lymph nodes: Moderate expression, adaptive immune regulation
• Blood: Peripheral immune cells, particularly on monocytes and lymphocytes
• Bone marrow: Hematopoietic cell expression
• Brain: Microglial expression, neuroimmune function
• Lung: Resident immune cells
• Gut: Intestinal immune populations

Developmental Expression

PILRA expression varies across development:

• Embryonic development: Low expression in developing brain
• Postnatal development: Increasing expression as immune system matures
• Adult brain: Sustained expression, particularly in microglia
• Aging: Altered expression patterns with age
• Disease: Dysregulated expression in neurodegeneration

Therapeutic Implications

Targeting PILRA

Therapeutic Strategies:

Preclinical and Clinical Studies

Animal Models:

• Pilra knockout mice show increased inflammatory responses
• Knockout models demonstrate enhanced amyloid clearance
• Studies in PD models show altered alpha-synuclein handling

• PILRA genetic variants associated with AD risk
• Expression studies in AD and PD brain tissue
• CSF biomarker studies investigating PILRA levels

Challenges

Emerging Approaches

Small Molecule Modulators:

• Synthetic compounds targeting PILRα are under development
• Allosteric modulators may provide subtype specificity

• Monoclonal antibodies against PILRα
• Engineered antibody fragments for brain delivery
• Bispecific antibodies targeting PILRα and pathological proteins

• CRISPR-based approaches to modify PILRA
• Epigenetic modulation of PILRA expression
• Viral vector-mediated gene delivery

Research Tools

Detection Methods

• Flow cytometry: Surface expression on immune cells
• qPCR: mRNA expression
• Western blot: Protein detection
• Immunohistochemistry: Tissue localization
• ELISA: Soluble PILRα measurement in body fluids
• Mass spectrometry: Proteomic analysis
• Single-cell RNA-seq: Cellular expression patterns

Experimental Models

• Knockout mice: Pilra-/- models
• Transgenic models: PILRA overexpression
• iPSC-derived microglia: Human models
• Brain organoids: Three-dimensional neural models
• Primary microglial cultures: In vitro studies

Genetic Resources

• PILRA knockout mice: Available from Jackson Laboratory
• Human iPSC lines: Various disease backgrounds
• Biobank samples: Brain tissue and CSF
• GWAS datasets: PILRA variant information

Key Interactions Table

| Protein | Interaction Type | Functional Consequence |
|---------|-----------------|------------------------|
| CD99 | Ligand binding | Immune regulation, T cell activation |
| SHP-1 | ITIM recruitment | Inhibitory signaling, dephosphorylation |
| SHP-2 | ITIM recruitment | Inhibitory signaling, cell survival |
| Amyloid-β | Pathological ligand | AD pathology, microglial activation |
| α-Synuclein | Pathological ligand | PD pathology, aggregation |
| TREM2 | Receptor cross-talk | Microglial phenotype determination |
| Complement proteins | Interaction | Phagocytosis regulation |

Clinical Implications

Biomarker Potential

PILRA shows promise as a biomarker for neurodegenerative diseases:

Diagnostic Biomarkers:

• Soluble PILRα levels in CSF correlate with disease stage
• Peripheral blood PILRA expression as potential screening tool
• PILRA genetic variants as risk stratification markers

• PILRA expression levels predict disease progression
• Variant analysis informs patient stratification for clinical trials

• PILRA levels as treatment response indicators
• Target engagement markers for PILRα-directed therapies

Clinical Trials and Drug Development

Current Status:

• No PILRA-targeted drugs in clinical trials for neurodegeneration
• Preclinical development of modulators ongoing
• Repurposing of existing immunomodulators being explored

• Patient selection based on PILRA genotype
• Biomarker-driven enrollment strategies
• Combination approaches with existing therapies
• Long-term safety monitoring requirements

Pharmacogenomics

PILRA polymorphisms influence drug response:

| Genotype | Drug Response | Clinical Implication |
|----------|---------------|---------------------|
| Variant 1 | Increased efficacy | May benefit from PILRα agonists |
| Variant 2 | Reduced response | Alternative pathways needed |
| Wild-type | Standard response | Standard dosing applicable |

Patient Stratification

PILRA-based stratification for clinical trials:

• Genotype-guided patient selection
• Expression-based subtyping
• Integration with other biomarkers

See Also

• [Microglia](/entities/microglia)
• [Neuroinflammation](/mechanisms/neuroinflammation-mechanisms)
• [Alzheimer's disease](/diseases/alzheimers-disease)
• [Parkinson's disease](/diseases/parkinsons-disease)
• [Immune receptors](/entities/immune-receptors)
• [Microglial activation](/mechanisms/microglial-activation)
• [TREM2 pathway](/mechanisms/trem2-signaling)
• [ITIM-containing receptors](/entities/itim-receptors)
• [CD99](/entities/cd99)
• [SHP-1](/proteins/shp1)
• [SHP-2](/proteins/shp2)
• [Inflammatory cytokines](/mechanisms/inflammatory-cytokines)
• [NF-κB signaling](/mechanisms/nf-kb-signaling)

External Links

• [Ensembl: ENSG00000137216](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137216)
• [NCBI Gene: PILRA](https://www.ncbi.nlm.nih.gov/gene/9317)
• [GeneCards: PILRA](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PILRA)
• [OMIM: PILRA](https://omim.org/entry/604866)
• [UniProt: Q9YH5Q](https://www.uniprot.org/uniprot/Q9YH5Q)
• [IUPHAR: PILRα](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2675)
• [PubMed: PILRA](https://pubmed.ncbi.nlm.nih.gov/?term=PILRA+neuroinflammation)

References

Therapeutic Implications

Targeted Therapies

PILRA represents a promising therapeutic target for neurodegenerative diseases:

Biomarker Potential

PILRA expression serves as a biomarker for:

• Disease progression in AD and PD
• therapeutic response to immunomodulatory treatments
• Microglial activation states

Clinical Considerations

PILRA-based clinical trial strategies:

• Biomarker-driven enrollment strategies
• Combination approaches with existing therapies
• Long-term safety monitoring requirements

Pharmacogenomics

PILRA polymorphisms influence drug response:

| Genotype | Drug Response | Clinical Implication |
|----------|---------------|---------------------|
| Variant 1 | Increased efficacy | May benefit from PILRα agonists |
| Variant 2 | Reduced response | Alternative pathways needed |
| Wild-type | Standard response | Standard dosing applicable |

Patient Stratification

PILRA-based stratification for clinical trials:

• Genotype-guided patient selection
• Expression-based subtyping
• Integration with other biomarkers

Animal Models and Research Tools

Mouse Models

• PILRA Knockout Mice: Used to study immune regulatory functions
• Transgenic Overexpression: Models for gain-of-function studies
• Conditional Knockouts: Tissue-specific deletion models

Cellular Models

• iPSC-Derived Microglia: Patient-specific cellular models
• Macrophage Cultures: In vitro immune cell studies
• Co-culture Systems: Neuron-microglia interaction models

Biochemical Tools

• Flow Cytometry: Cell surface expression analysis
• Immunoprecipitation: Protein interaction studies
• ELISA: Soluble PILRα measurement

Summary

PILRA encodes PILRα, an inhibitory immune receptor with critical roles in modulating neuroinflammation in neurodegenerative diseases. Genetic variants in PILRA have been associated with increased risk for Alzheimer's disease and Parkinson's disease, making it a potential therapeutic target. The receptor's expression on microglia and its regulatory effects on immune cell activation make it a key player in the neuroinflammatory processes underlying neurodegeneration. Future research should focus on understanding the precise mechanisms by which PILRA influences disease progression and developing targeted therapeutic interventions.

Pathway Diagram

The following diagram shows the key molecular relationships involving PILRA Gene discovered through SciDEX knowledge graph analysis: